-
公开(公告)号：US11497795B2
公开(公告)日：2022-11-15
申请号：US16657507
申请日：2019-10-18
发明人： Takumi Sakai , Genichi Kusakawa , Yugo Uchida
摘要： An object of the present invention is to provide an effective and safe medicament having effects for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by administration of an anti-malignant tumor agent, oxaliplatin, in a human cancer patient receiving an anti-malignant tumor treatment with oxaliplatin. There is provided a medicament for mitigating conditions and/or suppressing onset of a peripheral neuropathy induced by oxaliplatin in an anti-malignant tumor treatment consisting of repetition of a single cycle comprising intravenous administration of oxaliplatin to a human cancer patient and following drug withdrawal, which contains thrombomodulin for intravenously administering 0.06 mg/kg of thrombomodulin once per said single cycle of the treatment on the first day of each said cycle as an active ingredient.
-
公开(公告)号：US20220357334A1
公开(公告)日：2022-11-10
申请号：US17623517
申请日：2020-06-30
发明人： Akiko HONJO , Yuki UEDA , Shota KONNO
摘要： Provided is a glycated protein assay reagent containing at least a Trinder reagent, 4-aminoantipyrine, protease, a stabilizer of the protease, and ferrocyanide, wherein at least the Trinder reagent is contained in a Trinder reagent-containing partial composition, at least the 4-aminoantipyrine is contained in a 4-aminoantipyrine-containing partial composition, the stabilizer of the protease is a stabilizer that increases the oxidation-reduction potential of the ferrocyanide above 0.058 V when the stabilizer of the protease and the ferrocyanide are mixed, and the oxidation-reduction potential is an oxidation-reduction potential in a reaction system containing the stabilizer of the protease and the ferrocyanide and not containing glycated protein.
-
公开(公告)号：US10988468B2
公开(公告)日：2021-04-27
申请号：US16333510
申请日：2018-12-25
发明人： Daisuke Shikanai , Noriko Ishiguro
IPC分类号： C07D417/14 , A61P41/00 , A61P19/00
摘要： A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.
-
公开(公告)号：US20210085667A1
公开(公告)日：2021-03-25
申请号：US17112097
申请日：2020-12-04
发明人： Hirohide NOGUCHI , Yoshimasa ARANO , Kazuo ANDO , Kazuki TOYOSHIMA , Toshihiko SONE , Koki MATSUBARA
IPC分类号： A61K31/47 , C07D215/06
摘要： The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the P2X7 receptor.
-
公开(公告)号：US20200347046A1
公开(公告)日：2020-11-05
申请号：US16333510
申请日：2018-12-25
发明人： Daisuke SHIKANAI , Noriko ISHIGURO , Osamu OMORI
IPC分类号： C07D417/14 , A61P19/00 , A61P41/00
摘要： A novel compound represented by the following general formula (1), or a salt thereof, which has a superior EP4 receptor agonist activity, and a medicament containing the compound or a salt thereof as an active ingredient, which can be used for promotion of osteogenesis, therapeutic treatment and/or promotion of healing of fracture and the like.
-
公开(公告)号：US20200002744A1
公开(公告)日：2020-01-02
申请号：US16306936
申请日：2017-06-15
摘要： An object of the present invention is to provide a highly versatile, simple and safe method for measuring Lp-PLA2 activity. Another object of the present invention is to provide an accurate and highly sensitive method for measuring Lp-PLA2 activity. Provided is a method for measuring lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in a sample containing Lp-PLA2, the method comprising the following steps (A) to (C): (A) converting PAFs into lyso-PAFs by reacting the PAFs with the Lp-PLA2 in the sample; (B) hydrolyzing the lyso-PAFs produced in the step (A) with an enzyme (lyso-PAF-PLD) to obtain hydrolysate; and (C) measuring Lp-PLA2 activity in the sample by utilizing a quantitative change attributable to the hydrolysate obtained in step (B) as an indicator.
-
公开(公告)号：US09592275B2
公开(公告)日：2017-03-14
申请号：US14358115
申请日：2012-11-14
发明人： Kazuhisa Tsuruta , Yoshikazu Aoki , Yutaka Osawa , Inder Kaul
CPC分类号： A61K38/366 , A61K9/0019 , A61K38/00 , A61K38/177 , A61K38/57 , C12N15/09
摘要： A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.
-
公开(公告)号：US09555080B2
公开(公告)日：2017-01-31
申请号：US15226195
申请日：2016-08-02
发明人： Kazuhisa Tsuruta , Yoshikazu Aoki , Yutaka Osawa , Inder Kaul
CPC分类号： A61K38/366 , A61K9/0019 , A61K38/00 , A61K38/177 , A61K38/57 , C12N15/09
摘要： A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.
摘要翻译： 一种用于治疗和/或改善伴有一种或多种器官功能障碍的严重败血症患者的败血症的药物，其中从所述患者获得的血浆样本的国际标准化比率（INR）大于1.4，其包括 血栓调节素作为活性成分。
-
公开(公告)号：US09006225B2
公开(公告)日：2015-04-14
申请号：US12355143
申请日：2009-01-16
申请人： Kazumi Suzuki
发明人： Kazumi Suzuki
IPC分类号： A01N43/00 , A61K31/33 , C07C27/00 , A61K31/196 , A61K9/20 , A61K31/404 , A61K31/416 , A61K31/4365 , A61K31/60 , A61K47/36 , A61K47/38
CPC分类号： A61K31/196 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K31/404 , A61K31/416 , A61K31/4365 , A61K31/60 , A61K47/36 , A61K47/38 , A61K2300/00
摘要： A pharmaceutical composition which includes a compound represented by the general formula (I): or a salt thereof, and a pharmaceutically acceptable carrier, wherein the composition does not substantially contain a reducing sugar and/or a carrier containing a reducing sugar as an ingredient as the pharmaceutically acceptable carrier, or when the composition contains a reducing sugar and/or a carrier containing a reducing sugar as an ingredient as the pharmaceutically acceptable carrier, contact of the reducing sugar and the compound represented by the general formula (I) or a salt thereof is eliminated.
摘要翻译： 一种药物组合物，其包含由通式（I）表示的化合物或其盐和药学上可接受的载体，其中所述组合物基本上不含有还原糖和/或含有还原糖作为成分的载体 药学上可接受的载体，或者当组合物含有还原糖和/或含有还原糖作为药学上可接受的载体的成分的载体时，还原糖与通式（I）表示的化合物或盐的接触 被消除。
-
公开(公告)号：US20130237482A1
公开(公告)日：2013-09-12
申请号：US13676248
申请日：2012-11-14
申请人： Kazuhisa TSURUTA , Yoshikazu AOKI , Yutaka OSAWA , Inder KAUL
发明人： Kazuhisa TSURUTA , Yoshikazu AOKI , Yutaka OSAWA , Inder KAUL
IPC分类号： A61K38/57
CPC分类号： A61K38/366 , A61K9/0019 , A61K38/00 , A61K38/177 , A61K38/57 , C12N15/09
摘要： A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.
-
-
-
-
-
-
-
-
-
搜索结果
164 条记录 (耗时 0.041 秒)
